Aza-indazole compounds for use in tendon and/or ligament injuries

A compound of formula (I) or a pharmaceutically acceptable salt thereof

• wherein,
• R1 is selected from C1-C3alkyl and halogen;
• R2 is selected from NHSO2(CH2)nR3 and SO2NR5R6;
• n is 0 or 1;
• R3 is selected from phenyl optionally substituted once or more than once with R4;
• C3-C6cycloalkyl optionally substituted with hydroxyl;
• and a fused bicyclic aromatic ring system;
• R4 is independently selected from halogen, C1-C3alkoxy, cyano, C1-C3alkyl, hydroxyl, haloC1-C3alkyl, NHC(O)CH3, haloC1-C3alkoxy, and SO2NH(CH3);
• or
• two R4 at adjacent carbon atoms form a 5- or 6-membered heterocyclic non-aromatic ring comprising at least one heteroatom selected from N, O, or S said heterocyclic ring being fused to the phenyl ring and being optionally substituted with C(O)CH3;
• R5 is selected from H and C1-C3alkyl;
• R6 is selected from a C3-C6cycloalkyl optionally substituted once or more than once with R7;
• phenyl optionally substituted once or more than once with halogen;
• C1-C6alkyl optionally substituted with hydroxyl;
• 4- to 6-membered heterocyclic non-aromatic ring comprising at least one heteroatom selected from N, O or S optionally substituted once or more than once with oxo;
• and benzyl;
• R7 is independently selected from hydroxyl, haloC1-C3alkyl, halogen, C1-C3alkyl, C(O)OH, and hydroxyC1-C3alkyl;
• or
• R5 and R6 together with the N atom to which they are attached form a 4-, 5- or 6-membered heterocyclic non-aromatic ring optionally comprising one additional heteroatom selected from N, O or S, said ring being optionally substituted once or more than once with R8;
• a 6- to 8-membered saturated bicyclic ring system;
• R8 is independently selected from halogen;
• hydroxyC1-C3alkyl;
• C(O)NH2;
• hydroxyl;
• haloC1-C3alkyl optionally substituted with hydroxyl;
• phenoxy;
• and SO2C1-C3alkyl.